Send to

Choose Destination
J Antimicrob Chemother. 2004 May;53(5):797-803. Epub 2004 Mar 17.

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.

Author information

Department of Infection, GKT School of Medicine, St Thomas' Hospital Campus, London, UK.



We compared the in vitro activity of telavancin with that of vancomycin, teicoplanin, linezolid, quinupristin/dalfopristin, moxifloxacin and ampicillin, penicillin or oxacillin as appropriate, by the NCCLS/EUCAST and BSAC methods.


The organisms (n = 401) included in the study were patient isolates from St Thomas' Hospital and were selected to include representatives of the clinically important Gram-positive aerobic species. Susceptibility testing was performed by agar dilution methods on Mueller-Hinton agar according to the NCCLS/EUCAST guidelines, in comparison with Iso-Sensitest agar according to the BSAC guidelines.


Telavancin was active against all the Gram-positive species tested and nearly 90% of isolates included in the study had telavancin MICs </= 1 mg/L. Vancomycin-resistant enterococci and lactobacilli isolates with vancomycin MICs > 64 mg/L had telavancin MIC ranges of 0.5-8 and 2-16 mg/L, respectively. There was no evidence of cross-resistance with other comparator drugs. The results for telavancin for the two susceptibility testing methods were mostly either the same or within one doubling dilution.


The susceptibility breakpoints for telavancin have yet to be established, but it would appear that telavancin has superior potency to the other tested glycopeptides, and on a weight-for-weight basis displays activity that is comparable to, or better than, that of the other agents tested.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center